Therefore, targeting ERBB receptor family members like EGFR, ERBB2 or ERBB3 alone or in combination with other epithelial markers such as EpCAM, will provide opportunities to detect and isolate CTCs that represent primary tumors of ovarian and glioblastoma. This evidence concerns the gene EGFR and glioblastoma.